Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 621 • 2015 ACR/ARHP Annual Meeting
Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus
Astrid Rasmussen¹, Lida Radfar², Kiely Grundahl³, David M. Lewis⁴, Donald U Stone^5,6, C. Erick Kaufman⁷, Daniel J Wallace⁸, Michael H. Weisman⁹, Swamy Venuturupalli¹⁰, Christopher J Lessard¹¹, Biji Kurien¹², Juan-Manuel Anaya¹³, Michael D. Rohrer¹⁴, Raj Gopalakrishnan¹⁵, Glen D Houston¹⁶, James Chodosh¹⁷, Pamela J Hughes¹⁸, Nelson L. Rhodus¹⁹, John Ice¹, Kimberly Hefner²⁰, Jennifer A. Kelly²¹, Kathy L. Sivils¹ and R. Hal Scofield^1,22,23, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁴College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, ⁶Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center, West Hollywood, CA, ¹¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁴Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁵Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, ¹⁶Heartland Pathology, Oklahoma City, OK, ¹⁷Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹⁸Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, ¹⁹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁰Hefner Eye Care and Optical Center, Oklahoma City, OK, ²¹Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²³US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: The diagnosis of Sjögren′s Syndrome (SS) is often difficult and many patients are symptomatic for years with other diagnoses before confirmation of SS. Overlapping…
Abstract Number: 639 • 2015 ACR/ARHP Annual Meeting
Association Between Insomnia and EULAR Sjögren’s Syndrome Patient-Reported Index in Korean Patients with Primary Sjögren’s Syndrome
Jaehyung Hur¹, Sang Wan Chung¹, You Jung Ha², Eun Ha Kang³, Yeong Wook Song⁴ and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea, ³Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ⁵Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea
Background/Purpose: EULAR Sjögren's syndrome Patient-Reported Index (ESSPRI) is an index to evaluate symptom severity and recommended as an efficacy measure for clinical trials in primary…
Abstract Number: 1776 • 2015 ACR/ARHP Annual Meeting
Significantly Reduced Lymphadenopathy, Salivary Gland Infiltrates and Proteinuria in MRL-Lpr/Lpr Mice Treated with Ultrasoluble Curcumin/Turmeric: Increased Survival with Curcumin Treatment
Biji T Kurien^1,2,3, Valerie M Harris^1,4, Syed MS Quadri^1,4, Patricia Coutinho-de Souza¹, Joshua Cavett^5,6, Amanda Moyer⁴, Bilal Ittiq⁷, Angela Metcalf⁶, Husayn Ramji⁸, Dat Truong⁸, Kristi A. Koelsch^4,9,10, Mike Centola¹¹, Adam Payne¹², D. Danda¹³ and R. Hal Scofield^1,14, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Allergy and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷University of Oklahoma Health Sciences Center, Oklahoma, OK, ⁸University of Oklahoma, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ¹⁰Department Veterans Affairs Medical Center, Oklahoma City, OK, ¹¹Haus Bioceuticals, Oklahoma City, OK, ¹²Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ¹³Christian Medical College, Vellore, India, ¹⁴US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Commercial curcumin (CU), derived from food spice turmeric, has been widely studied as a potential therapeutic for a variety of oncological and inflammatory conditions.…
Abstract Number: 2800 • 2015 ACR/ARHP Annual Meeting
Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT
Sandra Gofinet Pasoto¹, Kristopherson Lustosa Augusto¹, Jackeline Couto Alvarenga², Liliam Takayama¹, Valéria Caparbo³, Ricardo M. Oliveira⁴, Eloisa Bonfá¹ and Rosa M R Pereira¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴RDO Diagnósticos Médicos, São Paulo, Brazil
Background/Purpose: To evaluate bone mineral density (BMD), microarchitecture, strength and prevalence of vertebral fractures (VF) in primary Sjögren's syndrome (pSS).Methods: We evaluated 71 female pSS…
Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Frederick B Vivino¹, Gary Foulks², S. Lance Forstot³, Peter Donshik⁴, Joseph Forstot⁵, Michael Goldstein⁶, Michael Lemp⁷, J. Daniel Nelson^8,9, Kelly K. Nichols^10,11, Stephen C. Pflugfelder¹², Jason Tanzer¹³, Penny Asbell¹⁴, Deborah S. Jacobs^15,16, Katherine M Hammitt¹⁷ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, ³Corneal Consultants of Colorado, Littleton, CO, ⁴Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, ⁵Rheumatology Associates of South Florida, Boca Raton, FL, ⁶New England Eye Center, Tufts Medical Center, Boston, MA, ⁷Department of Ophthalmology, Georgetown University, Washington, DC, ⁸Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, ⁹Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, ¹⁰School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, ¹¹College of Optometry, (formerly) University of Houston, Houston, TX, ¹²Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, ¹³Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, ¹⁴Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁵Boston Foundation for Sight, Needham, MA, ¹⁶Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, ¹⁷Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms. Clinical practice guidelines were…
Abstract Number: 641 • 2015 ACR/ARHP Annual Meeting
Pain, Xerostomia and Younger Age Are Major Determinants of Fatigue in Korean Primary Sjögren’s Syndrome Patients: A Comprehensive Analysis of a Cohort Study
JungHee Koh¹, Seung-Ki Kwok², Min Kyung Chung³, Jennifer Lee³, Ji Yeon Lee⁴ and Sung-Hwan Park³, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Fatigue is a common clinical manifestation in patients with primary Sjögren¡¯s syndrome (PSS). The aims of this study were to investigate the association between…
Abstract Number: 1871 • 2015 ACR/ARHP Annual Meeting
Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families
Rufei Lu¹, Hua Chen¹, Krista Bean¹, Teresa Aberle¹, Joel Guthridge¹ and Judith James^1,2, ¹Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine & Pathology, Univ. of Oklahoma, Okla, OK
Background/Purpose: Many systemic autoimmune diseases share heritable and non-heritable risks, as well as some clinical manifestations. A recent meta-analysis based upon genome-wide genetic studies contrasting…
Abstract Number: 2801 • 2015 ACR/ARHP Annual Meeting
Tofacitinib Suppresses Lymphocytic Infiltration in the Salivary Gland of Non-Obese Diabetic Mice; The Animal Model of Sjögren’s Syndrome
Jennifer Lee¹, Ji Yeon Lee², Jung Hee Koh³, Min Kyung Chung⁴, Ji Hun Kim¹, Seung-Ki Kwok⁵, Ji Hyeon Ju² and Sung-Hwan Park⁶, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea
Background/Purpose: Interferon signatures are upregulated in patients with primary Sjogren’s syndrome (pSS) and interferons are considered to have a pathogenic role in pSS. As Janus…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 643 • 2015 ACR/ARHP Annual Meeting
Ethnicity of Sjögren’s Syndrome
Rohan Sharma¹, Astrid Rasmussen², Lida Radfar³, David M. Lewis⁴, Kiely Grundahl⁵, C. Erick Kaufman⁶, Donald U. Stone⁷, Joan T. Merrill⁸, Christopher Lessard⁹, Kathy L. Sivils⁹ and Robert Hal Scofield¹⁰, ¹Medical Service, US Department of Veterans Affaris Medical Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, ⁴College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁶Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁷Ophthalmology, University of Oklahoam Health Sciences Center; Dean McGee Eye Center, Oklahoma City, OK, ⁸Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: We undertook this study to describe the racial and ethnic diversity of SS compared to that found among patients with SLE. SLE is known…
Abstract Number: 2014 • 2015 ACR/ARHP Annual Meeting
Deficiency of IL-27 Exacerbate Sjögren’s Syndrome through Inhibiting Differentiation of Type 1 Regulatory T Cells
Genhong Yao¹, Bingyu Shi¹, Jingjing Qi¹, Ying Wang¹, Weiwei Chen¹, Xiaojun Tang¹, Dandan Wang², Xuebing Feng¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Sjögren's Syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation involving the exocrine glands, particularly the salivary and lacrimal glands. The pathogenesis…
Abstract Number: 2803 • 2015 ACR/ARHP Annual Meeting
Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting
Naomi I Maria¹, Cornelia G. van Helden-Meeuwsen¹, Eline C. Steenwijk¹, Arne S. IJpma², Zana Brkic¹, Paul L. van Daele^1,3, P. Martin van Hagen^1,3, Peter J. van der Spek², Hemmo A. Drexhage¹, Wan-Fai Ng⁴ and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Bioinformatics, Erasmus Medical Center, Rotterdam, Netherlands, ³Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease with a large heterogeneity in clinical phenotype. The IFN type I signature is present in…
Abstract Number: 624 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention
Frederick B Vivino¹, Domenick Zero², Michael Brennan³, Troy Daniels⁴, Carol Stewart⁵, Athena Papas⁶, Andres Pinto⁷, James Sciubba⁸, Ibtisam Al-Hashimi⁹, Mahvash Navazesh¹⁰, Nelson L. Rhodus¹¹, Mabi Singh¹², Ava Wu¹³, Philip Fox¹⁴, Stephen Cohen¹⁵, Theresa Lawrence Ford¹⁶, Sharon Tracy¹⁷, Julie Frantsve-Hawley¹⁷, Katherine M. Hammitt¹⁴ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Indiana University School of Dentistry, Indianapolis, IN, ³Carolinas Medical Center, Charlotte, NC, ⁴Orofacial Sciences, UCSF School of Medicine & Dentistry, San Francisco, CA, ⁵University of Florida College of Dentistry, Gainesville, FL, ⁶Oral Medicine, Tufts University, Boston, MA, ⁷Case Western Reserve University, Cleveland, OH, ⁸The John Hopkins School of Medicine, Baltimore, MD, ⁹Baylor College of Dentistry, Dallas, TX, ¹⁰University of Southern California, Los Angeles, CA, ¹¹Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, ¹²Tufts University School of Dental Medicine, Boston, MA, ¹³University of California School of Dentistry, San Francisco, CA, ¹⁴Sjögren's Syndrome Foundation, Bethesda, MD, ¹⁵Dr. Stephen Cohen-Doctor My Eyes, Scottsdale, AZ, ¹⁶North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁷American Dental Association, Chicago, IL
Background/Purpose: Salivary dysfunction in Sjögren’s (SS) can lead to serious and costly oral complications including accelerated caries and, in some cases, loss of dentition. Clinical…
Abstract Number: 646 • 2015 ACR/ARHP Annual Meeting
Sicca Syndrome in Rheumatoid Arthritis: Is It a Real Sjögren’s?
George Fragoulis¹, James Reilly¹, Shauna Kerr¹, Iain. B. McInnes¹ and Haralampos M. Moutsopoulos², ¹Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: The histopathological hallmark and a major diagnostic criterion of Sjögren’s syndrome (SS) is the presence of periductal lymphocytic infiltrates in the labial minor salivary…
Abstract Number: 2100 • 2015 ACR/ARHP Annual Meeting
Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome
Juliana Imgenberg-Kreuz¹, Johanna K Sandling^1,2, Jonas Carlsson Almlöf¹, Jessica Nordlund¹, Linnea Signér², Katrine B Norheim³, Roald Omdal³, Majia-Leena Eloranta², Lars Rönnblom², Ann-Christine Syvänen¹ and Gunnel Nordmark², ¹Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Epigenetic modifications have emerged as important contributing factors in the pathogenesis of autoimmune diseases, including primary Sjögren’s syndrome (pSS), and may act as a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].